Here is a short,sweet statement from MedPage Today follow-up to the story I ran a few days ago about FDA’s dark mood concerning Avastin when used for breast cancer:

Wednesday June 29, 2011

FDA Panel Votes to Yank Avastin’s Breast Ca Indication

SILVER SPRING, Md. — An FDA advisory committee has voted unanimously, 6-0, that Genentech’s bevacizumab (Avastin) should no longer be approved to treat metastatic HER2-negative breast cancer. The panel was convened at Genentech’s request to appeal the agency’s earlier decision to remove the indication. 

Pattie has a good friend who has a family member who is currently using Avastin for a brain tumor.  This type of use is unaffected by the FDA’s ruling.  Bottom line:  The stats on this drug when used against breast cancer are horrible!  I feel bad for the women for which it seems to work.  I believe it can still be used off-label.  But insurance may not pay now…

Feel good and keep smiling!  Pat

Leave a Reply